Customize your JAMA Network experience by selecting one or more topics from the list below.
Dr Badruddoja's letter raises many questions. First, there is currently no controversy regarding the choice between TG and partial gastrectomy for gastric cancer. Total gastrectomy is actually the treatment of choice for upper gastric cancer and middle gastric cancer, in which a proximal 5-cm disease-free margin cannot be obtained.
Lower cancers and those located in the middle, where it is possible to achieve a 5-cm proximal margin, are best treated with a distal subtotal gastrectomy.1 Given its retrospective nature, our study (which encompass a long period of time) also includes a group of patients with antral cancer who underwent, during the early years of our experience, the so-called de principe TG, which was subsequently abandoned.
Second, the article by Sasako et al2 (which was performed differently from ours) includes only patients who were operated on with curative intent. Actually, the reported overall 5-year survival rate (69.2%) after D2 dissection compares with that reported in our article (61.8%), when only curative D2 TG is considered. Including patients with stage IV disease in the calculation of the overall survival may be confounding. Moreover, if only curative resections are considered, the survival reported in our article is undoubtedly higher compared with those recently reported in a Western series.3,4
Third, as far as palliative surgery is concerned, given the reported good palliations of symptoms and better survival rates in patients after resections compared with those without operations or with bypass procedures for stage IV disease, we think that, in specialized centers, TG could be considered worthwhile in upper and middle cancers, even in the palliative setting.
Fourth, regarding the extent of nodal dissection, we absolutely do not accept D1 dissection as the standard of care. This concept is mostly related to the results of the Dutch study,5 which, though it was heavily criticized because of the bias of the trial,6,7 had a negative influence on Western surgeons treating this curable disease. Indeed, it has been demonstrated that extended lymphadenectomy can be safely and effectively performed by Western surgeons.8 Moreover, the introduction of techniques that preserve the pancreas has reduced postoperative complications.9
The differences between Western and Eastern patients are not based on different behaviors of gastric cancer, but rely mostly on the different attitudes of Japanese and Eastern surgeons, especially when the extent of nodal dissection is concerned. In fact, in the ongoing Western trials on adjuvant therapies (Medical Research Council Adjuvant Gastric Infusional Chemotherapy II and Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer trials), D2 dissection is considered the standard and represents an inclusion criteria.
Finally, the report of long-term metabolic and nutritional effect of TG was beyond the purpose of our study. However, it is well demonstrated10 that the roux-en-Y reconstruction, which we routinely use, avoids alkaline reflux esophagitis and reduces postprandial symptoms to a very low rate. As a consequence, most patients can achieve an adequate caloric intake, thus overcoming the problem of relative malabsorption after TG.
Correspondence: Dr Pacelli, Digestive Surgery Unit, Istituto di Clinica Chirurgica, Catholic University–School of Medicine, Largo A. Gemelli 8, 00168 Rome, Italy (firstname.lastname@example.org).
Author Contributions:Study concept and design: Pacelli and Rosa. Acquisition of data: Pacelli and Rosa. Analysis and interpretation of data: Pacelli, Rosa, and Doglietto. Drafting of the manuscript: Pacelli. Critical revision of the manuscript for important intellectual content: Pacelli, Rosa, and Doglietto. Administrative, technical, and material support: Rosa. Study supervision: Pacelli and Doglietto.
Financial Disclosure: None reported.
Pacelli F, Rosa F, Doglietto GB. Total Gastrectomy—Reply. Arch Surg. 2009;144(3):289–292. doi:10.1001/archsurg.2008.585
Coronavirus Resource Center
Create a personal account or sign in to: